Werewolf Therapeutics (NASDAQ:HOWL) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWLFree Report) in a report published on Monday morning, Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Wedbush reissued an outperform rating and set a $9.00 price target on shares of Werewolf Therapeutics in a research report on Monday, May 6th. JMP Securities reissued a market outperform rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a research note on Monday, May 6th.

Read Our Latest Research Report on Werewolf Therapeutics

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock opened at $3.99 on Monday. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.24. The firm’s 50-day simple moving average is $5.58 and its 200 day simple moving average is $5.07. Werewolf Therapeutics has a 52 week low of $1.57 and a 52 week high of $8.19. The firm has a market capitalization of $173.41 million, a PE ratio of -3.66 and a beta of 0.62.

Werewolf Therapeutics (NASDAQ:HOWLGet Free Report) last released its quarterly earnings results on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.15%. The business had revenue of $0.74 million during the quarter, compared to analyst estimates of $5.00 million. On average, equities research analysts predict that Werewolf Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Janus Henderson Group PLC acquired a new position in Werewolf Therapeutics in the first quarter valued at $10,922,000. PFM Health Sciences LP grew its holdings in Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares during the period. Vanguard Group Inc. increased its stake in shares of Werewolf Therapeutics by 26.8% during the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after acquiring an additional 233,909 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 119.8% during the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after acquiring an additional 94,212 shares during the period. Finally, Denali Advisors LLC acquired a new stake in shares of Werewolf Therapeutics in the first quarter worth approximately $172,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Further Reading

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.